Every 424B that Microbot Med Inc (MBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBOT filings page.
Microbot Medical Inc. proposes an at-the-market offering to sell up to $39,230,691 aggregate offering price of its common stock through H.C. Wainwright & Co., acting as sales agent, under an amended sales agreement.
As of December 31, 2025, Microbot reported 67,158,044 shares outstanding; the prospectus shows an as adjusted figure of 83,851,955 shares reflecting an assumed sale of 16,693,911 shares at an illustrative price of $2.35 per share (the April 8, 2026 closing price referenced). The offering permits sales on Nasdaq or by other methods permitted as an ATM; Wainwright’s commission is 3.0% of gross proceeds. The company discloses intended use of proceeds for LIBERTY® development, regulatory and commercialization activities, potential IP acquisitions, and general corporate purposes, and notes ongoing risks related to regional hostilities in Israel that could affect operations.
Microbot Medical Inc. is registering up to 14,688,572 shares of common stock for resale by existing selling stockholders, issuable upon exercise of outstanding preferred investment options. The company itself is not selling shares in this offering and will not receive proceeds from any resale, although it may receive up to approximately $64.8 million in gross proceeds if all 14,688,572 options are exercised for cash, which would be used for working capital. Shares outstanding were 67,158,044 as of November 14, 2025. Microbot highlights recent progress for its LIBERTY® Endovascular Robotic Surgical System, including U.S. FDA 510(k) clearance in September 2025 and ISO 13485:2016 certification, and notes plans to pursue CE Mark approval in the second half of 2026. The company also discusses new patents in Japan, China and the U.S., and outlines risks related to ongoing regional military conflicts affecting its Israel-based operations.
Microbot Medical Inc. is registering up to 900,153 shares of common stock for resale by certain selling stockholders, consisting of shares issuable upon exercise of outstanding preferred investment options. The company is not selling any shares in this offering and will not receive proceeds from stockholder resales, though it may receive up to approximately $2.1 million in gross proceeds if all 900,153 options are exercised for cash.
Microbot is a medical device company developing next-generation robotic systems for minimally invasive endovascular procedures, led by its LIBERTY® Endovascular Robotic Surgical System. On September 8, 2025, LIBERTY received FDA 510(k) clearance for peripheral endovascular procedures, and a limited U.S. market release began on November 5, 2025, with a broader launch anticipated in April 2026. The company reports recent patents in Japan, the United States, and China, ISO 13485:2016 certification supporting a CE Mark it anticipates in the second half of 2026, and collaboration with Emory University on autonomous robotics. It also discusses risks from ongoing military conflict affecting its Israel-based operations, noting no material adverse effects as of the prospectus date but no specific contingency plans.